Asta Medica, Aktiengesellschaft

Asta Pharma Aktiengesellschaft

Zentaris Ag

Zentaris Gmbh

Asta-werke Aktiengesellschaft, Chemische Fabrik

Asta Medica Aktiengellschaft

Peter Hilgard

Jurgen Engel

Bernhard Kutscher

Wolfgang Schumacher

Gerhard Nossner

Jurij Stekar

Thomas Klenner

Bernd Nickel

J&uuml;rgen Engel

Rainer Voegeli

Henri Brunner

Friedrich Maiterth

Peter Hankofer

Gerhard N&ouml;ssner

Axel Kleemann

Dieter Sauerbier

Thomas Reissmann

Werner Sarlikiotis

Ulf Niemeyer

Juergen Engel

Jorg Pohl

Eckhard Milsmann

Margrit Stekar

Johannes Respondek

Karin Klokkers-Bethke

Thomas Reissman

Jurij Stekar, Deceased

Joerg Pohl

A method of treating protozoal and fungal diseases is described, in which an effective amount of a compound of formula I is administered to a host having a protozoal or fungal disease. Also described are methods of treating bone marrow damage composed of administering, to a host having bone marrow damage due to treatment with cytostatic agents or other myelotoxic active ingredients, an effective amount of a compound of formula I

Disease treatment with novel phospholipid derivatives

The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

Use of dopamine receptor antagonists in palliative tumor therapy

The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.

Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis

Methods of using therapeutic phospholipid derivatives

Phospholipid derivatives

Phospholipid derivatives containing higher elements of the Vth main group (P, As, Sb, Bi), their method of preparation and antineoplastic and antimicrobially active medications that can be prepared from the phospholipid derivatives.

Phospholipid derivatives containing higher elements of the fifth main

Poorly soluble salts of LHRH analogues, for example cetrorelix embonate, display an intrinsic sustained release effect in the grain size 5 .mu.m to 200 .mu.m.

Long-acting injection suspensions and a process for their preparation

For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of Cetrorelix acetate and one or more maintenance doses of Cetrorelix acetate, Cetrorelix embonate or a slow-release form of Cetrorelix, is used as a combination preparation for treatment to be administered at specific time intervals.

Products for administering an initial high dose of Cetrorelix and

Phospholipid derivatives containing higher elements of the fifth group

Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N-CR.sub.2 &lt; forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural part --CR.sub.2 &lt; represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 &lt; represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also being possible for the phenyl ring of this group R.sub.2 to be substituted by hydroxy, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -alkyl, C.sub.2 -C.sub.6 -alkanoyloxy or halogen; the radicals R.sub.3 and R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl and X stands for the equivalent of a physiologically acceptable anion or X can also be a water molecule, where in the latter case the missing negative charge is saturated by a corresponding physiologically acceptable acid anion, where in the case of platinum(II) complexes, two of the groups X are absent.

Ethylene-substituted phenylalkylethylenediamine-platinum (II or IV)

Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphate and a process for its preparation. This compound is useful for the treatment of cancer.

Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphate and a process for its

Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N--CR.sub.2 &lt;forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural part --CR.sub.2 &lt; represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 &lt; represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also being possible for the phenyl ring of this group R.sub.2 to be substituted by hydroxy, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -alkyl, C.sub.2 -C.sub.6 -alkanoyloxy or halogen; the radicals R.sub.3 and R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl and X stands for the equivalent of a physiologically acceptable anion or X can also be a water molecule, where in the latter case the missing negative charge is saturated by a corresponding physiologically acceptable acid anion, where in the case of platinum(II) complexes, two of the groups X are absent.

Ethylene-substituted phenylalkylethylene-diamine-platinum (II or IV)

Growing community of inventors

Frankfurt-am-Main, Germany

Peter Hilgard